A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Compound Glycyrrhizin Capsules Combined with a Topical Corticosteroid in Adults with Chronic Eczema
Table 2
Baseline patient demographics (FAS).
Characteristic
Total N = 193
Control N = 99
Treated N = 94
t/χ2
Age (y)
Mean (SD)
43.64 (13.89)
42.25 (14.33)
45.10 (13.32)
1.43
0.16
Range, min-max (y)
18–73
18–69
22–73
Age distribution
18–39 y
70
29
41
40–59 y
93
49
44
≥60 y
30
16
14
Sex, male, n (%)
71 (36.8%)
40 (40.4%)
31 (33.0%)
1.14
0.29
Height (cm), mean (SD)
165.07 (8.00)
165.29 (8.85)
164.85 (7.08)
−0.37
0.71
Weight (kg), mean (SD)
63.65(12.60)
63.06(9.75)
64.27(15.07)
0.67
0.51
BMI, mean (SD)
23.29 (3.96)
23.05 (2.88)
23.55 (4.84)
0.87
0.39
Baseline IGA, n (%)
Moderate (Grade 3)
79 (40.9)
37 (39.4)
42(42.4)
0.187
0.665
Severe (Grade 4)
114(59.1)
57(60.6)
57(60.6)
BSA (%)
Mean (SD)
10.88 (2.54)
10.94 (2.75)
10.71 (2.01)
0.034
0.967
Range, min-max
6–14
6–13
5–14
EASI
Mean (SD)
10.29 (1.09)
10.35 (1.16)
10.23 (1.07)
0.72
0.452
Range, min-max
7.89–13.23
7.67–13.31
BSA: body surface area; IGA: Investigator’s Global Assessment score; EASI: Eczema Area and Severity Index.
